Cytarabine therapy for refractory cutaneous lupus.
Yung
R L
RL
University of Michigan, Ann Arbor, USA.
Richardson
B C
BC
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D017294:Ondansetron / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D017294:Ondansetron